Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. With a distinguished team including co-founder and CRISPR-Cas genome editing co-inventor Jennifer Doudna, Mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.
Our leadership team is comprised of cutting edge scientific research and business achievement.
Dr. Trevor Martin founded Mammoth Biosciences with the mission to enable the next generation of CRISPR-based synthetic biology products across therapeutics and diagnostics, including a novel class of affordable, effective, and rapid CRISPR-enabled molecular diagnostics that allow individuals worldwide to better understand their health and a novel family of CRISPR Cas14 proteins that can enable in-vivo editing.
Trevor earned his BA from Princeton University and his PhD in Biology from Stanford. His work has been featured in outlets including FiveThirtyEight and The Atlantic. He is the featured healthcare honoree on the Forbes 30 Under 30 list, is on Fortune’s 40 Under 40 list, and is a Malaria No More “10 to END” innovator.
As co-founder and Chief Technology Officer of Mammoth Biosciences, Janice leads the Applied program by implementing CRISPR-based DETECTR technology towards disease detection and other areas. Janice received her Ph.D. in Molecular and Cell Biology in Jennifer Doudna's lab at UC Berkeley. She has authored multiple publications and patents related to CRISPR mechanism and technologies, and co-invented the programmable CRISPR-based detection technology called DETECTR. Janice was selected as a 2019 Forbes 30 Under 30 in Healthcare, and delivered a TEDx talk in 2018 on the potential for CRISPR to democratize diagnostics.
As co-founder and Chief Science Officer of Mammoth Biosciences, Lucas drives the development of next-generation CRISPR products and leads the scientific research program for new discoveries. He focuses on harnessing microbial diversity to build novel CRISPR applications for DNA detection and genome editing. At UC Berkeley, Lucas worked in Jennifer Doudna’s lab and authored multiple scientific papers, the latest of which features his discovery of the newest Cas system to date, Cas14, in Science. He received a BS in Chemistry from Washington University in St. Louis, where he researched bacterial photosynthesis.
Co-founder, Chair of Scientific Advisory Board
As an internationally renowned professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, Doudna and her colleagues rocked the research world in 2012 by discovering a simple way of editing the DNA of any organism using an RNA-guided protein found in bacteria, known as CRISPR. Doudna is an Investigator with the Howard Hughes Medical Institute and a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences. She is also a Foreign Member of the Royal Society and has received many other honors including, the Breakthrough Prize in Life Sciences, the Heineken Prize, the BBVA Foundation Frontiers of Knowledge Award and the Japan Prize.
Chief Business Officer & Head of Therapeutics
Peter joined Mammoth from Casebia Therapeutics as Chief Business Officer and Head of Therapeutics. Peter co-founded Casebia as a Joint Venture between Bayer HealthCare and CRISPR Therapeutics and as part of the leadership team moved several assets from concept to preclinical stage. He brings in more than 19 years of pharma and biotech experience to drive Mammoth’s corporate strategy and enable the translation of technology into applications. Prior to Casebia, Peter has been at Bayer in various positions with increasing responsibility both in the US and in Germany covering strategic marketing, business development, project management, and R&D. Peter received his Ph.D. in Organic Chemistry from the University of Marburg followed by postdoctoral studies at Stanford University. He has co-authored more than 45 patents and various scientific publications.
Gary joined Mammoth from Sangamo, where he was EVP, General Counsel and Chief Compliance Officer. Gary has also been General Counsel at several Bay Area biotechnology companies including Amyris, Achaogen and Counsyl. In addition to serving in operational roles leading business development, human resources, facilities, IT, and regulatory, Gary has deep expertise in licensing and intellectual property. He was at Genentech for over 11 years, ultimately leading the intellectual property, litigation, and corporate records functions as VP of Intellectual Property. Gary earned his J.D. from Columbia Law School and his B.S. (Biological Sciences) and B.A. (English) from Stanford University. Gary has lectured as an Adjunct Professor at the University of San Francisco School of Law since 2006.
Vice President of Research and Development
VP of R&D, Jesus Ching, Ph.D. brings 30 years of experience building innovative technologies in the in vitro diagnostics space to lead the development of Mammoth’s next-generation CRISPR tools. Jesus kicked off his career directing and launching diagnostics products at Cepheid. Afterward, he co-founded and sold GenturaDx to Luminex Corporation, and has since held various C-Suite positions at organizations ranging from Click Diagnostics to Coyote Biosciences, where he set technical and IP strategy. Jesus received his Ph.D. in Chemistry from Baylor University.
Vice President of Product Development
As VP of Product Development, Tim Patno leverages 30 years of extensive regulatory and product development experience to oversee the manufacturing of Mammoth Biosciences’ diagnostics products. Prior to Mammoth, Tim spent nine years at Baxter Healthcare, then went on to develop and launch Nanosphere’s Verigene system. Most recently, Tim built and launched multiple products for large and small companies’ integrated molecular diagnostic assays. Tim has his Masters in Electrical Engineering from the University of Southern California.
After over 30 years representing biotechnology companies at a prominent intellectual property law firm and as general counsel at a start-up through a successful IPO and subsequent merger, Bill serves as Mammoth’s in-house legal counsel. Although, primarily focusing on worldwide patent strategy in the rapidly developing CRISPR field, he brings considerable experience in building successful companies to the Mammoth team.
VP of Intellectual Property and Associate General Counsel
VP of IP, Rachel Herder, Ph.D. leads Mammoth Biosciences’ robust IP strategy. She joins the team with eight years of experience as a patent attorney representing startups, both at a leading intellectual property law firm and as the Director of the Intellectual Property Clinic at Penn State Law. Rachel has focused her career on representing clients in the genome editing and gene diagnostic spaces and has advised startup life science clients on various aspects of intellectual property law, including patent prosecution, litigation, and global patent strategy. Rachel received both her J.D. and Ph.D. in Molecular Cellular Developmental Biology & Genetics from Michael B. O'Connor's lab at the University of Minnesota.
Chief Operations Officer
Ted is an experienced Chief Operations Officer at Mammoth Biosciences, where he oversees Mammoth’s go-to-market strategy and growth. After four years at Synthego Corporation, he grew the company from 18 to 250 employees and established product development, manufacturing operations, and commercial programs. Previously, Ted served as Vice President-General Manager for the Protein Function Division at Bio-Rad Laboratories with responsibilities spanning bioprocessing, multiplex immunoassay, imaging, and life science education programs.
VP of Finance
VP of Finance, Susan Wong brings over 25 years of corporate financial management and accounting experience to her position, over half of which has been in the venture-backed companies in the life sciences industry. Prior to joining Mammoth Biosciences, she was VP of Finance at Neurona Therapeutics where she led the finance and accounting functions. In her span of career, Susan held leadership positions serving in the capacity of CFO/Controller consultants at Osprey Pharmaceuticals, Cerimon Pharmaceuticals, Epiphany Biosciences and Cellerant Therapeutics. She was an educator and had taught finance and accounting courses at UC Berkeley extension and Menlo College. Susan received a BS degree from University of Hawaii, a Master of Business Administration from Santa Clara University and Master of Accountancy from Golden Gate University.